MwanzoGSK ⢠NYSE
add
GSK plc
Bei iliyotangulia
$Â 59.54
Bei za siku
$Â 58.05 - $Â 59.07
Bei za mwaka
$Â 32.38 - $Â 61.70
Thamani ya kampuni katika soko
118.63B USD
Wastani wa hisa zilizouzwa
6.42M
Uwiano wa bei na mapato
15.43
Mgao wa faida
3.07%
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (GBP) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 8.62B | 6.17% |
Matumizi ya uendeshaji wa biashara | 4.57B | -0.28% |
Mapato halisi | 636.00M | 53.62% |
Kiwango cha faida halisi | 7.38 | 44.71% |
Mapato kwa kila hisa | â | â |
EBITDA | 2.50B | 35.38% |
Asilimia ya kodi ya mapato | 23.47% | â |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (GBP) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 3.41B | -21.27% |
Jumla ya mali | 61.12B | 2.78% |
Jumla ya dhima | 45.16B | -2.62% |
Jumla ya hisa | 15.96B | â |
hisa zilizosalia | 4.01B | â |
Uwiano wa bei na thamani | 14.59 | â |
Faida inayotokana na mali | 5.87% | â |
Faida inayotokana mtaji | 10.70% | â |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (GBP) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 636.00M | 53.62% |
Pesa kutokana na shughuli | 2.28B | -2.19% |
Pesa kutokana na uwekezaji | -933.00M | 16.62% |
Pesa kutokana na ufadhili | -856.00M | -1.66% |
Mabadiliko halisi ya pesa taslimu | 448.00M | 19.47% |
Mtiririko huru wa pesa | 1.15B | -49.69% |
Kuhusu
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
27 Des 2000
Tovuti
Wafanyakazi
68,629
